Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026

Core Viewpoint - Edgewise Therapeutics is set to present at the Leerink Global Healthcare Conference on March 11, 2026, highlighting its focus on developing novel therapeutics for muscle diseases and cardiac conditions [1]. Company Overview - Edgewise Therapeutics, Inc. is a biopharmaceutical company specializing in muscle diseases, particularly muscular dystrophies and serious cardiac conditions [1]. - The company is recognized for its expertise in muscle physiology, which is driving the development of a new generation of therapeutics [1]. Key Products in Development - Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor currently in late-stage clinical trials for Becker and Duchenne muscular dystrophies [1]. - EDG-7500 is a novel cardiac sarcomere modulator in Phase 2 clinical development aimed at treating symptomatic hypertrophic cardiomyopathy [1]. - EDG-15400 is another cardiac sarcomere modulator in Phase 1 clinical development targeting heart failure [1]. Mission Statement - The company is dedicated to changing the lives of patients and families affected by serious muscle diseases [1].